Design of Coltuximab Ravtansine, a CD19-Targeting Antibody–Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure–Activity Relationships and Preclinical Evaluation-Reference-Cited by-同舟云学术

Design of Coltuximab Ravtansine, a CD19-Targeting Antibody–Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure–Activity Relationships and Preclinical Evaluation

Published:2015-04-27 Issue:6 Volume:12 Page:1703-1716
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Hong E. Erica¹,Erickson Hans¹,Lutz Robert J.¹,Whiteman Kathleen R.¹,Jones Gregory¹,Kovtun Yelena¹,Blanc Veronique²,Lambert John M.¹

Affiliation:

1. ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451, United States

2. Sanofi, 13 quai Jules Guesde, Vitry sur Seine, 94403 France

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.5b00175

Reference46 articles.

1. Cancer Statistics, 2008

2. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

3. Effective Immunochemotherapy For Aggressive Non-Hodgkin’s Lymphoma

4. Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab–Auristatin Conjugate with a Wide Therapeutic Window;Molecular Cancer Therapeutics;2024-04-01

2. Innovations in Antibody-Drug Conjugate (ADC) in the Treatment of Lymphoma;Cancers;2024-02-18

3. Use of Payload Binding Selectivity Enhancers to Improve Therapeutic Index of Maytansinoid–Antibody–Drug Conjugates;Molecular Cancer Therapeutics;2023-07-25

4. Cyclic carbamates in medicine: A clinical perspective;Drug Development Research;2023-01-18

5. Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer;Clinical Medicine Insights: Oncology;2023-01